Phase 2CompletedHealthspan endpoint
A Study of Fesoterodine and Oxybutynin on Cognitive Function in Mild Cognitive Impairment
A Double Blind, Randomized Four Way Cross Over Study to Compare the Effect of Fesoterodine 4mg and 8mg Once Daily and Oxybutynin 5mg Twice Daily After Steady State Dosing Versus Placebo on Cognitive Function in Subjects With Overactive Bladder, Over the Age of 75 Years With Mild Cognitive Impairment
- Sponsor
- University of Alberta (Academic or other)
- Enrollment
- 47 enrolled
- Conditions
- Overactive Bladder; Mild Cognitive Impairment
- Interventions
- fesoterodine 4mg; Oxybutynin; placebo; fesoterodine 8mg
- Ages
- older adults
- Registry
- NCT02240459
Full record on ClinicalTrials.gov
From the registry
The purpose of this study is to assess the effects of fesoterodine at 4mg and 8mg doses versus a placebo and oxybutynin 5mg bid versus placebo on cognitive abilities in older people with overactive bladder and mild cognitive impairment.
Primary outcomes
- continuity of attention
History
Last registry update
Primary completion
Started
Registered